BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Allaire M, Goumard C, Lim C, Le Cleach A, Wagner M, Scatton O. New frontiers in liver resection for hepatocellular carcinoma. JHEP Rep. 2020;2:100134. [PMID: 32695968 DOI: 10.1016/j.jhepr.2020.100134] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Lee YT, Wang JJ, Luu M, Noureddin M, Kosari K, Agopian VG, Rich NE, Lu SC, Tseng HR, Nissen NN, Singal AG, Yang JD. The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States. J Natl Cancer Inst 2021:djab079. [PMID: 34010422 DOI: 10.1093/jnci/djab079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Li S, Chen S, Dong Z, Song X, Li X, Huang Z, Li H, Huang L, Zhuang G, Lan R, Guo M, Li W, Saw PE, Zhang L. Concurrent silencing of TBCE and drug delivery to overcome platinum-based resistance in liver cancer. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.03.003] [Reference Citation Analysis]
3 Desert R, Ge X, Song Z, Han H, Lantvit D, Chen W, Das S, Athavale D, Abraham-Enachescu I, Blajszczak C, Chen Y, Musso O, Guzman G, Hoshida Y, Nieto N. Role of Hepatocyte-Derived Osteopontin in Liver Carcinogenesis. Hepatol Commun 2021. [PMID: 34730871 DOI: 10.1002/hep4.1845] [Reference Citation Analysis]
4 Ye D, Liu Y, Li G, Sun B, Peng J, Xu Q. A New Risk Score Based on Eight Hepatocellular Carcinoma- Immune Gene Expression Can Predict the Prognosis of the Patients. Front Oncol 2021;11:766072. [PMID: 34868990 DOI: 10.3389/fonc.2021.766072] [Reference Citation Analysis]
5 Bai XM, Yang W. Radiofrequency ablation of hepatocellular carcinoma: Prognostic factors and recent advances. Shijie Huaren Xiaohua Zazhi 2021; 29(13): 677-683 [DOI: 10.11569/wcjd.v29.i13.677] [Reference Citation Analysis]
6 Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing Epidemiology of Hepatocellular Carcinoma in Asia. Liver Int 2022. [PMID: 35319165 DOI: 10.1111/liv.15251] [Reference Citation Analysis]
7 Allaire M, Rudler M, Thabut D. Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses…. Liver Int 2021;41:1734-43. [PMID: 34051060 DOI: 10.1111/liv.14977] [Reference Citation Analysis]
8 Zhang Y, Li M, Qiu Y, Wu Y, Chen S, Ni B, Tang D, Deng Z, Hu Z. MiR-139-5p/ENAH Affects Progression of Hepatocellular Carcinoma Cells. Biochem Genet 2022. [PMID: 35254597 DOI: 10.1007/s10528-022-10204-9] [Reference Citation Analysis]
9 Govalan R, Lauzon M, Luu M, Ahn JC, Kosari K, Todo T, Kim IK, Noureddin M, Kuo A, Walid AS, Sundaram V, Lu SC, Roberts LR, Singal AG, Heimbach JK, Agopian VG, Nissen N, Yang JD. Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis. Liver Cancer 2021;10:407-18. [PMID: 34721504 DOI: 10.1159/000515554] [Reference Citation Analysis]
10 Yeh H, Chiang CC, Yen TH. Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. World J Gastroenterol 2021; 27(26): 4104-4142 [PMID: 34326614 DOI: 10.3748/wjg.v27.i26.4104] [Reference Citation Analysis]